Quantum-computing company Xanadu and the University of Alberta are teaming up to design better cancer drugs of an unusual kind — ones that are activated by light.
Announced August 14, 2026, the collaboration — with University of Alberta chemistry professor Alex Brown — will develop quantum algorithms to speed the design of photosensitizers, the molecules at the heart of photodynamic therapy. In that non-invasive cancer treatment, a photosensitizer is given and then activated with light, generating reactive species that kill nearby tumor cells.
Why quantum
Designing a good photosensitizer is hard because its performance depends on complex excited-state behavior — how the molecule absorbs light and hands off energy. “Photosensitisers are challenging systems because their performance depends on excited-state processes,” Brown said. Classical simulations are slow, costly or miss critical quantum interactions; the partners will build a quantum-computing framework to simulate these light-matter interactions and pinpoint which molecules best trigger cancer-cell death at the right wavelengths.
The bigger bet
Quantum computers are still early, but chemistry — simulating molecules and their electrons — is one of the most promising near-term uses. For Xanadu, the project extends its quantum drug-design workflow into a concrete, high-value problem. It’s early-stage research, not a product, but a sign of how quantum methods are inching into real drug discovery.